Displaying 921 - 940 of 1540
FTC Warns Marketers of Children's Omega-3 Fatty Acid Supplements That Claims About Brain and Vision Benefits May Be Deceptive
FTC Settles Charges That Colorado Physicians Group Director Attempted to Evade Terms of 2008 Price-Fixing Order
Colorado Physicians Group Agrees to Stop Alleged Price-Fixing Tactics
Commission Approves FY 2011 Budget Request and GPRA Performance Plans for Submission to Congress; FTC Staff: Proposed Kentucky Regulations for Licensing Retail Clinics Raise Competitive Concerns; FTC Issues Annual Financial Acts Enforcement Report to
FTC Approves Final Consent Order in Case of Pfizer Inc. and Wyeth
FTC Order Preserves Competition in Market for Important Scientific Research Device, While Allowing Danaher to Proceed with Purchase of MDS Analytical Technologies
Commission Seeks Public Comments on Carilion Clinics Application to Divest Center for Surgical Excellence to Fairlawn Surgery Center, LLC; FTC Approves The Dow Chemical Companys Petition to Divest its Acrylic Acid and Latex Polymers Businesses to Arkema
Commission Announces Revised Filing Thresholds for Clayton Act Antitrust Reviews; Commission Retains Amplifier Rule; Final Consent Orders against Six Businesses That Claimed to Comply With an International Privacy Framework
Watson Pharmaceuticals, Inc., a corporation, and Robin Hood Holdings Limited, a limited liability company, In the Matter of
The Commission charged that Watson Pharmaceuticals, Inc.’s acquisition of Robin Hood Holdings Limited, owner of Arrow Pharmaceuticals, would have harmed consumers by eliminating future competition for important generic drugs used to treat Parkinson’s disease (cabergoline) and the side effects of chemotherapy (dronabinol). The Commission’s order requires the firms to sell assets related to the two drugs to FTC-approved buyers and to ensure the acquirers have the means to compete effectively in the future.
There is a related federal proceeding and two related administrative proceedings:
FTC Chairman, Members of Congress Call for Legislation to End Sweetheart Pay-for-Delay Deals That Keep Generic Drugs Off the Market
FTC's Closure of Its Investigation of Consummated Hospital Merger in Temple, Texas
Bureau of Competition Director Issues Statement on FTCs Closure of its Investigation of Consummated Hospital Merger in Temple, Texas
FTC Order Ensures Future Competition for Parkinsons and Chemotherapy Drugs That Watsons Acquisition of Arrow Would Have Eliminated
Commission Issues 2009 Report on U.S. Ethanol Market Concentration; FTC Approves Final Consent Order in Matter Concerning Carilion Clinic
FTC Order Restores Competition Lost Through Schering-Plough's Acquisition of Merck
Statement of FTC Chairman Jon Leibowitz On Passage of H.R. 3126, the Consumer Financial Protection Act of 2009 by the House Energy and Commerce Committee
U.S. Court of Appeals Enforces Subpoenas in FTCs Androgel Investigation; In Separate Case, FTC Files Petition to Compel Enforcement of Subpoena Issued to Boehringer Ingelheim
Displaying 921 - 940 of 1540